Get the Stockscreener App
14.34
7.42%
0.99
After Hours:
14.30
-0.04
-0.28%
Tonix Pharmaceuticals Holding Corp stock is traded at $14.34, with a volume of 657.22K.
It is up +7.42% in the last 24 hours and up +8.31% over the past month.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
See More
Previous Close:
$13.35
Open:
$13.35
24h Volume:
657.22K
Relative Volume:
1.60
Market Cap:
$203.71M
Revenue:
$13.11M
Net Income/Loss:
$-124.02M
P/E Ratio:
-1.0055
EPS:
-14.261
Net Cash Flow:
$-107.25M
1W Performance:
+9.97%
1M Performance:
+8.31%
6M Performance:
-26.46%
1Y Performance:
-15.65%
1-Day Range:
$13.35
$14.40
1-Week Range:
$12.19
$14.40
52-Week Range:
$11.60
$69.97
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Name
Tonix Pharmaceuticals Holding Corp
Sector
Industry
Phone
212-980-9155
Address
200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NY
Compare TNXP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
14.34 | 189.64M | 13.11M | -124.02M | -107.25M | -14.26 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-18-22 | Initiated | Noble Capital Markets | Outperform |
| Apr-18-19 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-18-17 | Upgrade | ROTH Capital | Neutral → Buy |
| Sep-07-16 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-17-16 | Reiterated | Oppenheimer | Outperform |
| Nov-04-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-12-15 | Initiated | Oppenheimer | Outperform |
| Feb-17-15 | Reiterated | ROTH Capital | Buy |
| Sep-29-14 | Reiterated | ROTH Capital | Buy |
View All
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Latest News
Tonix Pharmaceuticals (TNXP) Reports Positive Findings on TNX-10 - GuruFocus
Tonix publishes pharmacokinetic study on fibromyalgia drug - Investing.com
20-day study maps how Tonix’s fibromyalgia drug acts overnight - Stock Titan
Analyst Upgrade: Can Tonix Pharmaceuticals Holding Corp stock outperform in a bear marketWeekly Earnings Recap & Reliable Price Breakout Alerts - baoquankhu1.vn
TNXP Stock Price, Quote & Chart | TONIX PHARMACEUTICALS HOLDIN (NASDAQ:TNXP) - ChartMill
TNXP Options Volatility — NASDAQ:TNXP - TradingView — Track All Markets
TNXP Options Chain — NASDAQ:TNXP - TradingView — Track All Markets
Profit Recap: Will Tonix Pharmaceuticals Holding Corp announce a stock split2026 Analyst Calls & Daily Chart Pattern Signals - baoquankhu1.vn
Will Tonix Pharmaceuticals Holding Corp stock benefit from M AInflation Watch & Daily Stock Trend Watchlist - baoquankhu1.vn
Why Tonix's External Atty Saw GC Role As A 'Natural Choice' - Law360
Tonix Pharmaceuticals stock hits new 52-week low: What's driving the action? - MSN
Liquidity Mapping Around (TNXP) Price Events - Stock Traders Daily
Tonix Pharmaceuticals Holding Corp at TD Cowen Healthcare Conference Transcript - GuruFocus
Tonix Pharma CEO Lederman buys $63,099 in shares By Investing.com - Investing.com South Africa
Tonix Pharma CEO Lederman buys $63,099 in shares - Investing.com
Tonix (NASDAQ: TNXP) CEO adds 5,000 shares via IRA purchase - Stock Titan
Tonix Pharmaceuticals Holding Corp. (TNXP) stock price, news, quote and history - Yahoo Finance Australia
Tonix plans Phase 2 Lyme disease prevention study in 2027 By Investing.com - Investing.com Australia
Tonix Pharmaceuticals Holding Corp Presents Phase 1 Data And Outlines Planned Adaptive Phase 2 Field Study Of TNX-4800 For Prevention Of Lyme Disease - marketscreener.com
Tonix Pharma Advances TNX-4800 Lyme Disease Prevention Program - TipRanks
Tonix Pharmaceuticals (TNXP) Advances TNX-4800 Lyme Disease Trea - GuruFocus
Tonix plans Phase 2 Lyme disease prevention study in 2027 - Investing.com
Tonix Pharmaceuticals presents Phase 1 TNX-4800 data, aims for adaptive Phase 2 in H1 2027 - TradingView — Track All Markets
Tonix (Nasdaq: TNXP) advances TNX-4800 Lyme prevention antibody on Phase 1 data - Stock Titan
Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026 - GlobeNewswire
Recap Report: Can Tonix Pharmaceuticals Holding Corp stock outperform in a bear marketAnalyst Upgrade & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Tonix Pharmaceuticals Stock Hits New 52-Week Low: What's Driving The Action? - Benzinga
Tonix Pharmaceuticals (NASDAQ: TNXP) puts reverse split and 2026 equity plan to vote - Stock Titan
TNXP Should I Buy - Intellectia AI
TNXP SEC FilingsTonix Pharmaceut 10-K, 10-Q, 8-K Forms - Stock Titan
Tonix Pharmaceuticals (NASDAQ:TNXP) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Vanguard disaggregates holdings after realignment; reports 0 shares in Tonix (TNXP) - Stock Titan
Tonix Pharmaceuticals Holding Corp. Trade Ideas — BOATS:TNXP - TradingView
Tonix doses first patient in migraine treatment study By Investing.com - za.investing.com
Tonix Pharmaceuticals Begins Phase 1 Study of Intranasal Oxytocin (TNX-1900) for Migraine and Craniofacial Pain Treatment - Minichart
Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain - Bitget
Tonix Pharmaceuticals (TNXP) Advances with Phase 1 Study on TNX-1900 - gurufocus.com
Tonix Pharma Begins Phase 1 Study of TNX-1900 - TipRanks
Tonix doses first patient in migraine treatment study - Investing.com
Tonix (NASDAQ: TNXP) doses first subject in TNX-1900 migraine study - Stock Titan
Tonix Pharmaceuticals Holding Corp Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 - marketscreener.com
Q1 Earnings Forecast for TNXP Issued By Zacks Research - MarketBeat
FY2028 Earnings Estimate for TNXP Issued By Zacks Research - Defense World
Why (TNXP) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
FY2028 Earnings Forecast for TNXP Issued By Zacks Research - MarketBeat
Tonix Pharmaceuticals Holding Corp. (TNXP) Presents at BIO-Europe Spring 2026Slideshow - Seeking Alpha
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):